Technology Transfer

From Discovery to Successful Applications

From Discovery to Impact

The ultimate goal of biotechnological science is the transfer of reserach results into applications outside of academia. With our broad spectrum of approaches for the discovery and engineering of proteins tailored to particular industrial and clinical applications, we are well-endowed to take up this challenge.

Proven success

Antibodies are key reagents of modern diagnostics and therapy, and our department has a long track record of successful collaborations with health institutions, biotech and pharma industry. A variety of technology solutions and antibodies developed in the department have already been transferred to various successful applications - from catalog research antibodies and diagnostic kits to clinical applications against cancer or infectious diseases - via cooperations, outlicensing, technology transfer centres, and through several spin-off companies.


  • Yumab GmbH, human therapeutic antibody discovery and engineering services. Highlight: Yumab reported the rapid generation of fully human antibodies neutralising SARS-CoV2, the virus responsible for the worldwide Corona pandemic (more info here and here)
Norden Vaccines

English press release, German press release

News and Awards related to Tech Transfer:


4/23/2021 - First COVID-19 patients treated with COR-101 drug developed in Braunschweig.
CORAT Therapeutics GmbH announced the start of a clinical trial with COR-101 for treatment of COVID-19 in hospitalized patients. The molecule was disvovered at the TU Braunschweig by the Corona Antibody Team (CORAT) in the Lab of Stefan Dübel and Michael Hust. The novel therapeutic antibody is planned to complement currently approved antibody drugs, which are not indicated for moderate to severe COVID-19 cases due to side effects during advanced stages of the disease.

press release of CORAT Therapeutics

Website of CORAT Therapeutics

Original paper on COR-101


Bispecific antibody

March 29, 2021 - Braunschweig antibody in clinical trials in the USA: New Drug Grips Tumor Cells With Two Arms.

The first patients with advanced tumors have been treated with a novel antibody-based in a clinical trial in the USA. It uses an invention of the Technical University of Braunschweig: The team of Professor Stefan Dübel, head of the Department of Biotechnology, discovered a human antibody that targets tumor cells and developed it over many years. This antibody is now part of a complex novel compound against difficult-to-treat cancers that is undergoing clinical testing by the pharmaceutical company Merck.

read more:  english - german


COR-101 is tested in clinical trials

March 16, 2021 - CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase I/Ib trial with the SARS-CoV-2 neutralizing human antibody COR-101.

The study ( ID: NCT04674566) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, first-in-human, phase I/Ib study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of COR-101 in hospitalized patients with moderate to severe COVID-19.

Download press release (PDF)

Das PANDAAlarmRed

3/2021 - The team of the Department of Biotechnology led by Dr. Maren Schubert won the second prize in the CHALLENE ONE HEALTH HACKATHON for their project "PANDAAlarmRed", an early warning structure against future emerging zoonotic virus diseases than may cause the next pandemics.

COR-101 ready for clinical trials

11/2020 - From discovery to clinic-ready within less than a year: CORAT's therapeutic antibody COR-101 against SARS-CoV-2 is produced for the first clinical trials

more information (PDF): Deutsch - english 

12/2020 - Three of our startups won in three of the four categories of the Durchstarterpreis 2020:

11/2020 Abcalis won the Innovation Award 2020 of Göttingen, Special Award Science and Education.

  • Video presenting the concept
Abcalis and Corat win 2020 Innovation Award
Dr. Bernd Althusman, Minister of Economy, Labor, Transport and Digitalization, presents Abcalis with the Innovation Award 2020

9/2020 - Double success! From 120 applicants, our teams were selected to win two of the three Lower Saxony Innovation Awards for 2020:

press release

website of Innovation Award

Falling Walls Winner

CORAT is one of the winners at 2020 FallingWalls Science Conference in Berlin


5/2020 A new EU commission white paper on animal use for antibody generation prominently acknowledges the animal-free multiclonal antibodies invented by the TU Braunschweig spinoff/EXIST founder team ABCALIS.

Download report - Summary in Nature

CORAT member YUMAB generated protective coronavirus antibody
Dr. Thomas Schirrmann und Dr. André Frenzel, CORAT-Partner YUMAB

4/2020: Helping to fight against COVID19:
CORAT member YUMAB, spinoff of the Department of Biotechnology of the TU Braunschweig, generated a neutralising coronavirus antibody
protecting against SARS-CoV-2 infection, as confirmed by the Helmholtz Center for Infection Reserach

Prof. Dr. Hust und Dr. Viola Fühner

2020: "Founder of the month" - featured by the magazine "Wirtschaft"

Innovationspreis der Bioregionen

2019: Innovation Prize of the German Bioregions was awarded to our Norden Vaccines Team at the German Biotechnology Days in Wuerzburg, April 9th


2017: 1st prize of the Innovationsnetzwerk Niedersachsen was awarded to Yumab and the TU Braunschweig at the Hannover Messe by the Minister for Science and Culture, Gabriele Heinen-Kljajić, and the Minister for Economics, Employment and Traffic, Olaf Lies

2016: Technology transfer Award of the Chamber of Commerce Braunschweig

2015: Innovation in Biotechnology Award of the American Association of Pharmaceutical Scientists (AAPS)

2013: Entrepreneurship-Award of TU Braunschweig and Ostfalia

With entrepreneurship support from: